FluxG, BardiesM, ChiesaCet al.Clinical radionuclide therapy dosimetry: The quest for the “Holy Gray.”Eur J Nucl Med Mol Imaging, 2007; 34:1699.
4.
LoevingerR, BudingerTF, WatsonEE. MIRD Primer for Absorbed Dose Calculations, rev. ed.New York: The Society of Nuclear Medicine, 1991.
5.
DivoliA, ChiavassaS, FerrerLet al.Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies. J Nucl Med, 2009; 50:316.
6.
SharkeyRM, BrennerA, BurtonJet al.Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response?J Nucl Med, 2003; 44:2000.
7.
BransB, BodeiL, GiammarileFet al.Clinical radionuclide therapy dosimetry: The quest for the “Holy Gray” [review]Eur J Nucl Med Mol Imaging, 2007; 34:772.
8.
FerrerL, Kraeber-BodereF, Bodet-MilinCet al.Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer, 2010; 116,4suppl:1093.
9.
BuckleySE, ChittendenSJ, SaranFHet al.Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med, 2009; 50:1518.
10.
FluxGD, HaqM, ChittendenSJet al.A dose–effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 2010; 37:270.
PauwelsS, BaroneR, WalrandSet al.Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med, 2005; 46,suppl1:92S.
13.
BaroneR, Borson-ChazotF, ValkemaRet al.Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med, 2005; 46,suppl1:99S.
14.
StabinMG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 1996; 37:538;comment in J Nucl Med 1998;39:927.
15.
BouchetLG, BolchWE, BlancoHPet al.MIRD Pamphlet No 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med, 2003; 44:1113.
16.
KonijnenbergM, MelisM, ValkemaRet al.Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med, 2007; 48:134.
17.
WesselsBW, KonijnenbergMW, DaleRGet al.MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med, 2008; 49:1884.
18.
FowlerJF. 21 years of biologically effective dose. Br J Radiol, 2010; 83:554.
19.
FowlerJF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol, 1989; 62:679.
20.
LassmannM, BransB, BehrT. Introduction.1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. Cancer Biother Radiopharm, 2005; 20:45.
21.
LassmannM, ChiesaC, FluxGD, BardiesM. EANM Dosimetry Committee guidance document: Good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging, 2010; 37:in press.
